On October 21, 2022, the U.S Food and Drug Administration (FDA) approved tremelimumab in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (HCC).
For more information, read the FDA announcement and the AstraZeneca announcement.
Posted 10/24/2022
On June 1, 2026, CMS published its interim final rule (IFR), Medicaid Program; Community Engagement Requirement for Certain Individuals in the Federal Register, followed by a public comment period, during which time ACCC submitted a comment letter requesting amendments to the IFR.
